Truist analyst Danielle Brill raised the firm’s price target on BridgeBio (BBIO) to $102 from $95 and keeps a Buy rating on the shares. The firm notes that the Vyndamax IP settlement to mid-2031 represents an upside scenario to the company’s Attruby asset as its prior base case assumed loss of exclusivity by 2028-end, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- Zemansky Reiterates Buy on BridgeBio, Nudges Price Target to $96 on Attruby Edge and Reduced Tafamidis Patent Overhang
- BofA ups BridgeBio price target, cites exclusivity ‘disappointment’ for pullback
- Midday Fly By: OpenAI said to miss targets, Coca-Cola reports Q1 beat
- Pfizer Vyndamax settlement at lower end of expectations, says Morgan Stanley
- BridgeBio turns negative after Pfizer details tamidis settlement